Passage Bio, Inc. (PASG) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 7 Buy, 2 Hold.
The consensus price target is $6.00, representing a downside of 44.8% from the current price $10.86.
Analysts estimate Earnings Per Share (EPS) of $-19.70 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.07 vs est $-19.70 (beat +94.6%). 2025: actual $-14.35 vs est $-9.83 (missed -46%). Analyst accuracy: 0%.
PASG Stock — 12-Month Price Forecast
$6.00
▼ -44.75% Downside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Passage Bio, Inc., the price target is $6.00.
The average price target represents a -44.75% change from the last price of $10.86.
PASG Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Passage Bio, Inc. in the past 3 months
EPS Estimates — PASG
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.07
vs Est –$19.70
▲ 1,741.1% off
2025
Actual –$14.35
vs Est –$9.83
▼ 31.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — PASG
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
